Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_assertion type Assertion NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_head.
- NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_assertion description "[Here we show that CD34+/CD38- leukemia precursors have reduced in vitro sensitivity to daunorubicin, a major drug used in leukemia treatment, in comparison with the CD34+/CD38+ counterpart, and increased expression of multidrug resistance genes (mrp/lrp).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_provenance.
- NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_assertion evidence source_evidence_literature NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_provenance.
- NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_assertion SIO_000772 10969785 NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_provenance.
- NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_assertion wasDerivedFrom befree-2016 NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_provenance.
- NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_assertion wasGeneratedBy ECO_0000203 NP293838.RADJU019QJ87QVZmNRTrRDfB5JpZzkVosQAz_LzG2HO-c130_provenance.